搜索到 1000 条关于 ㈂ 사설토토 먹튀 ㉩ rfa609.top ㆂ 카지노 먹튀검증 ㅉ 선릉역야구장 ㉹ 토토 분석 프로그램 ㄼ 해외축구중계사이트 ㉴ 축구생방송중계 ㅯ 안전놀이터 모음 ㅞ 양방사이트 的文章

丁香园力荐 最受医生欢迎的 20 本必备好书

2015.11.14 丁香园力荐 最受医生欢迎的 20 本必备好书

「借花献佛」,和大家分享下推荐最多的 10 本 「案头必备」和 10 本 「床头必备」好书。一、案头必备TOP 1. 实用内科学推荐理由:中国医学界唯一一部畅销...出版一次,已出至第14版,可及时反映国内外进展,是内科领域各级学科医师的 「不二宝典」。TOP 2. 坎贝尔骨科手术学推荐理由:国际权威骨科经典著作,内含众多
2013年5大重磅新药

2013.12.27 2013年5大重磅新药

2013年岁末已至,回首这一年,一批「重磅炸弹」级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top1 默克...晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2 糖尿病治疗的新突破强生和Evotec公司共同开发
盘点2013年改变世界的5大重磅新药

2013.12.25 盘点2013年改变世界的5大重磅新药

2013年岁末已至,回首这一年,一批"重磅炸弹"级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top...积极的数据。制药巨头正准备将晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2:糖尿病治疗的新突破强生和Evotec公司
七夕节:话一话古代十大奇葩避孕方式

2016.08.09 七夕节:话一话古代十大奇葩避孕方式

CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入

中华医学会肿瘤消融规范化治疗培训班

网站(rfa.cmacme.org)。培训考核未通过者,可以在12个月内中华医学会肿瘤消融规范化治疗同类别培训班中任选一期免费参加学习(培训期间食宿费用自理...举办时间可能会有微调,详情请关注项目网站(rfa.cmacme.org)公布的最新通知。五、收费标准培训费3800元/人。食宿统一安排

中华医学会肿瘤消融规范化治疗培训班

(www.cma.org.cn)及项目网站(rfa.cmacme.org)。培训考核未通过者,可以在12个月内中华医学会肿瘤消融规范化治疗同类别培训班中任选一期免费参加学习(培训期间...严格控制在180人以内。具体举办时间可能会有微调,详情请关注项目网站(rfa.cmacme.org)公布的最新通知。五、收费标准培训费

中华医学会肿瘤消融规范化治疗培训班

(www.cma.org.cn)及项目网站(rfa.cmacme.org)。培训考核未通过者,可以在12个月内中华医学会肿瘤消融规范化治疗同类别培训班中任选一期免费参加学习(培训期间...(rfa.cmacme.org)公布的最新通知。五、收费标准 培训费3800元/人(含餐)。住宿统一安排,费用自理。具体住宿标准见培训班的二轮通知

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2013.03.16 TLR4通路基因多态性与肺炎相关性的研究现状

重要作用。目前已知TNFRSF1A有启动子区的-609G/T,-580A/G和-383A/C及第一外显子的+36A/G等SNP。在伴有血液疾病的侵袭性肺曲霉病患者中,TNFRSF1A +36A/G、-609A/G与侵袭性肺曲霉病易感性相关,且TNFR1-609G/T与TNFRl mRNA转录水平密切相关,携带TT基因型

2012.09.19 2010 第五届国际基因组学大会(ICG-V)

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
指南 | 2018 年美国肝病学会肝细胞癌治疗指南

2018.04.28 指南 | 2018 年美国肝病学会肝细胞癌治疗指南

HCC 患者(T1 或 T2 期)是否应接受切除或局部治疗(LRT)?推荐意见手术切除优于射频消融(RFA)。(证据质量:中;推荐强度:有条件)技术评论(1...肿瘤可能无法接受手术切除。(4)对 RFA 和手术切除进行比较的随机试验主要在东亚患者中进行。尚不清楚东西方人群统计学差异对不同治疗转归的影响。肝硬化是 HCC 的
病例挑战:房颤射频消融术后吞咽困难 1 例

2017.12.12 病例挑战:房颤射频消融术后吞咽困难 1 例

血性心脏病和心房颤动病史,此次就诊原因为新发食管性吞咽困难。一周前,为治疗房颤,他接受了冠状动脉搭桥手术,左心房射频消融术(RFA)。一开始,胃肠病专家对他进行了评估
微访谈问答集锦:陈敏山教授谈肝癌的多学科联合治疗

2015.12.27 微访谈问答集锦:陈敏山教授谈肝癌的多学科联合治疗

,如:射频联合 PEI(酒精注射)或者 TACE+射频消融(RFA)。
肝移植前局部治疗可提高肝细胞癌术后生存率

2015.10.15 肝移植前局部治疗可提高肝细胞癌术后生存率

;(TACE)和动脉放疗栓塞(TARE),而热射频消融包括射频消融(RFA)和微波消融(MWA),这两种方法均通过诱导肿瘤
恶性胰腺实性假乳头状瘤的手术方案

2014.08.04 恶性胰腺实性假乳头状瘤的手术方案

清扫。SPN可以转移至腹膜、肝及淋巴结,再次手术可以提高生存率,对于无手术指征的肝转移病人,RFA及肝移植值得尝试。本研究只纳入了SPN手术病人,虽然SPN病人常规推荐

2013年超声治疗“大家”论坛——超声无创治疗暑期学校

RFA)、经导管动脉栓塞术/经导管动脉化疗栓塞(TAE/TACE)、HIFU 治疗等等,为学员与全球的医生和专家学者们提供一个活跃的平台,以交流临床经验及最新
卒中后抗血小板出血风险有多大?有这10个特征需谨慎

2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎

)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
远程协作治疗创伤后应激障碍

2014.12.23 远程协作治疗创伤后应激障碍

明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N
上一页 1 2 3 ... 25 26 27 ... 48 49 50 下一页 到第